Clarivate (NYSE:CLVT) is one of the cheap penny stocks to invest in. On December 4, Clarivate announced the official launch of its Cortellis Regulatory Intelligence AI Assistant, which is a tool powered by agentic AI to help life sciences professionals navigate the complexities of safety and compliance. This release follows a successful beta phase conducted earlier in the year and is now available to all Cortellis Regulatory Intelligence customers.
The assistant is built on Clarivate’s established AI platform and integrates over 30 years of regulatory expertise trusted by leading pharmaceutical companies and international agencies. The AI assistant aims to transform how regulatory teams interpret shifting global requirements into actionable insights. It allows users to ask complex questions in natural language and receive precise, cited answers that maintain context throughout a conversation.
Key features include multilingual capabilities and the ability to summarize documents in seconds, providing clear, customized takeaways. Additionally, the tool can instantly compare draft and final guidance documents, saving professionals hours of manual labor and accelerating decision-making throughout the product lifecycle. The assistant is designed to deliver accurate intelligence from early-stage development to improve patient outcomes.
Clarivate (NYSE:CLVT) operates as an information services provider in the Americas, the Middle East, Africa, Europe, and the Asia Pacific. It operates through three segments: Academia & Government, Life Sciences & Healthcare, and Intellectual Property.
While we acknowledge the potential of CLVT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
